Sung Ji Nam
Stock Analyst at Scotiabank
(2.05)
# 2,775
Out of 4,945 analysts
83
Total ratings
40.58%
Success rate
-6.26%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $60.36 | -0.60% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $53.79 | +39.44% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $210.22 | +30.82% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $485.04 | +21.64% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $100.09 | +24.89% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $19.82 | +101.82% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.40 | +403.78% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.89 | +1.87% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.21 | +24.61% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.23 | +62.60% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $44.99 | +62.26% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $12.92 | -7.12% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $293.52 | +53.31% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $28.84 | +114.98% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $30.04 | +46.47% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $11.82 | +196.11% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.80 | +25.00% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.77 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $60.36
Upside: -0.60%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $53.79
Upside: +39.44%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $210.22
Upside: +30.82%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $485.04
Upside: +21.64%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $100.09
Upside: +24.89%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $19.82
Upside: +101.82%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.40
Upside: +403.78%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.89
Upside: +1.87%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.21
Upside: +24.61%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.23
Upside: +62.60%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $44.99
Upside: +62.26%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $12.92
Upside: -7.12%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $293.52
Upside: +53.31%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $28.84
Upside: +114.98%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $30.04
Upside: +46.47%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $11.82
Upside: +196.11%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.80
Upside: +25.00%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $21.77
Upside: -